Geode Capital Management LLC Lowers Position in OmniAb, Inc. (NASDAQ:OABI)

Geode Capital Management LLC trimmed its holdings in shares of OmniAb, Inc. (NASDAQ:OABI) by 0.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,325,381 shares of the company’s stock after selling 12,906 shares during the quarter. Geode Capital Management LLC owned 1.97% of OmniAb worth $9,838,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Atria Investments Inc acquired a new stake in shares of OmniAb during the third quarter valued at about $148,000. FMR LLC boosted its position in shares of OmniAb by 10.6% during the 3rd quarter. FMR LLC now owns 138,813 shares of the company’s stock worth $587,000 after purchasing an additional 13,324 shares during the period. Isthmus Partners LLC increased its holdings in OmniAb by 37.2% in the 2nd quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock valued at $1,981,000 after purchasing an additional 143,387 shares during the last quarter. Murchinson Ltd. purchased a new stake in OmniAb in the third quarter valued at approximately $4,230,000. Finally, Rice Hall James & Associates LLC lifted its stake in OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares in the last quarter. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

OmniAb Trading Down 0.6 %

OmniAb stock opened at $3.54 on Thursday. The firm has a market capitalization of $499.90 million, a P/E ratio of -5.71 and a beta of -0.14. OmniAb, Inc. has a twelve month low of $3.43 and a twelve month high of $6.72. The stock’s fifty day simple moving average is $3.92 and its 200-day simple moving average is $4.12.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.